Key Developments: Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

195.19USD
30 Jan 2015
Change (% chg)

$-4.81 (-2.40%)
Prev Close
$200.00
Open
$198.62
Day's High
$202.00
Day's Low
$195.00
Volume
1,471,641
Avg. Vol
1,221,527
52-wk High
$213.33
52-wk Low
$127.69

Search Stocks

Latest Key Developments (Source: Significant Developments)

Illumina Inc reaffirms FY 2015 guidance
Tuesday, 27 Jan 2015 04:05pm EST 

Illumina Inc:Projects about 20 pct FY 2015 revenue growth, assuming current currency exchange rates, and FY 2015 non-GAAP earnings per diluted share of $3.12 to $3.18.Reported revenue of $1.856 billion in FY 2014.FY 2015 revenue of $2.264 billion - Thomson Reuters I/B/E/S.  Full Article

Illumina Inc gives FY 2015 guidance; EPS guidance in line with analysts' estimates
Monday, 12 Jan 2015 02:00pm EST 

Illumina Inc:Expects FY 2015 revenue growth of 20pct.Expects FY 2015 non-GAAP EPS to be in the range of $3.12 to $3.18.FY 2015 EPS of $3.17 on revenue of $2.255 billion - Thomson Reuters I/B/E/S.  Full Article

Universities of Edinburgh and Glasgow are to partner with Illumina Inc
Sunday, 11 Jan 2015 07:00pm EST 

Illumina Inc:Says the Universities of Edinburgh and Glasgow are to partner with Illumina.The investment will establish The Scottish Genomes Partnership, which will install 15 HiSeq X sequencing instruments divided between two hubs within the Universities.  Full Article

Biomerieux agrees with Illumina to launch NGS epidemiology solution for service labs
Tuesday, 18 Nov 2014 01:00am EST 

Biomerieux SA:Signs exclusive agreement with Illumina to launch next-generation sequencing (NGS) epidemiology solution for service labs.Companies are to jointly develop applications for microbiology sequencing technologies within four-year renewable period.  Full Article

Illumina announces completion of IVD development and supply agreement with Illumina
Thursday, 30 Oct 2014 07:02am EDT 

Illumina Inc:Says HTG Molecular Diagnostics Inc enters into an agreement with the company under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.  Full Article

Illumina Inc raises FY 2014 guidance
Monday, 20 Oct 2014 06:05am EDT 

Illumina Inc:Increases FY 2014 revenue growth to 30 pct.Increases FY 2014 non-GAAP earnings per fully diluted share to $2.63 to $2.65.Reported revenue of $1.421 bln in fiscal 2013.FY 2014 revenue of $1,803 bln and EPS of $2.30 - Thomson Reuters I/B/E/S.  Full Article

Illumina Inc announces strategic partnerships with AstraZeneca, Janssen and Sanofi to redefine companion diagnostics for oncology
Thursday, 21 Aug 2014 02:00am EDT 

Illumina Inc:Says that it has formed collaborative partnerships with pharmaceutical companies to develop a universal sequencing (NGS) based oncology test system.Says the system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi.Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization.Says in parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.Says together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics.  Full Article

Illumina Inc and Cypher Genomics enter agreement to facilitate genomic biomarker discovery
Thursday, 24 Jul 2014 06:00am EDT 

Illumina Inc:Cypher Genomics Inc says a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called Coral.Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.  Full Article

Illumina Inc raises FY 2014 guidance
Wednesday, 23 Jul 2014 04:05pm EDT 

Illumina Inc:Raises FY 2014 guidance to 25 to 26 pct revenue growth.Raises FY 2014 non-GAAP earnings per fully diluted share to $2.26 to $2.28.Reported revenue of $1.421 bln in fiscal 2013.FY 2014 revenue of $1.758 bln and EPS of $2.17 - Thomson Reuters I/B/E/S.  Full Article

Illumina Inc announces acquisition Myraqa
Wednesday, 16 Jul 2014 06:30am EDT 

Illumina Inc:Has acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.Financial terms were not disclosed.  Full Article

Illumina teams with U.S. government, researchers to sequence Ebola

CHICAGO - Gene sequencing equipment maker Illumina has teamed up with the U.S. government and academic researchers at the Broad Institute in Boston to train scientists in West Africa to improve tracking of how the Ebola virus is mutating in hopes of fighting it more effectively.

Search Stocks